- Home
- DMLP vs ELVN Comparison
DMLP vs ELVN Comparison
Compare DMLP & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMLP
- ELVN
- Stock Information
- Founded
- DMLP 2003
- ELVN 2016
- Country
- DMLP United States
- ELVN United States
- Employees
- DMLP N/A
- ELVN N/A
- Industry
- DMLP Oil & Gas Production
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- DMLP Energy
- ELVN Health Care
- Exchange
- DMLP Nasdaq
- ELVN Nasdaq
- Market Cap
- DMLP 1.3B
- ELVN 1.2B
- IPO Year
- DMLP N/A
- ELVN 2020
- Fundamental
- Price
- DMLP $27.75
- ELVN $19.32
- Analyst Decision
- DMLP
- ELVN Strong Buy
- Analyst Count
- DMLP 0
- ELVN 5
- Target Price
- DMLP N/A
- ELVN $41.20
- AVG Volume (30 Days)
- DMLP 65.4K
- ELVN 410.5K
- Earning Date
- DMLP 08-08-2025
- ELVN 08-12-2025
- Dividend Yield
- DMLP 11.66%
- ELVN N/A
- EPS Growth
- DMLP N/A
- ELVN N/A
- EPS
- DMLP 2.03
- ELVN N/A
- Revenue
- DMLP $166,824,000.00
- ELVN N/A
- Revenue This Year
- DMLP N/A
- ELVN N/A
- Revenue Next Year
- DMLP N/A
- ELVN N/A
- P/E Ratio
- DMLP $13.80
- ELVN N/A
- Revenue Growth
- DMLP 12.09
- ELVN N/A
- 52 Week Low
- DMLP $25.84
- ELVN $13.30
- 52 Week High
- DMLP $34.88
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- DMLP 52.34
- ELVN 40.65
- Support Level
- DMLP $27.10
- ELVN $21.25
- Resistance Level
- DMLP $28.00
- ELVN $22.83
- Average True Range (ATR)
- DMLP 0.39
- ELVN 1.42
- MACD
- DMLP 0.05
- ELVN -0.35
- Stochastic Oscillator
- DMLP 72.22
- ELVN 5.60
About DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.